Flex Pharma, Inc. is a biopharmaceutical company dedicated to creating innovative, novel treatments for neuromuscular disorders. Flex Pharma has demonstrated initial human efficacy related to muscle cramping in healthy volunteers. The Company plans to initiate efficacy studies in patients with neuromuscular disorders in the first half of 2015.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 09/09/14 | $40,000,000 |
Alexandria Real Estate Equities Bindley Capital Partners CD Ventures City Hill Ventures EcoR1 Capital Jennison Associates Kraft Group Lightstone Ventures Longwood Fund Richard Mark Beleson Todd Dagres | undisclosed |
